4-[(6-Amino-pyridine-3-carbonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester | 1211443-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(6-Amino-pyridine-3-carbonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[(6-aminopyridine-3-carbonyl)amino]piperidine-1-carboxylate
• CAS: 1211443-92-3
• 化学式: C₁₆H₂₄N₄O₃
• 分子量: 320.392
• InChiKey: BQHJGOBXTNKKMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[(6-Amino-pyridine-3-carbonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 反应 2.0h， 以100%的产率得到6-amino-N-piperidin-4-ylpyridine-3-carboxamide
  参考文献：
  名称：

  Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists

  摘要：

  Nicotinamides of benzyl-substituted 4-aminopiperidines and their seven-membered analogs of generic structure 2 and 20 have been discovered as potent and selective SST5 antagonists. The activity (K-i) ranges from 2.4 to 436 nM. Most compounds exhibit decent physicochemical properties and follow a clear SAR pattern. Interestingly enough, the receptor is strongly enantiodiscriminating and binds in the amino-azepaneseries only the (R)-enantiomer. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.026
• 作为产物：
  描述：

  6-氨基烟酸 、 1-Boc-4-氨基哌啶 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 生成 4-[(6-Amino-pyridine-3-carbonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists

  摘要：

  Nicotinamides of benzyl-substituted 4-aminopiperidines and their seven-membered analogs of generic structure 2 and 20 have been discovered as potent and selective SST5 antagonists. The activity (K-i) ranges from 2.4 to 436 nM. Most compounds exhibit decent physicochemical properties and follow a clear SAR pattern. Interestingly enough, the receptor is strongly enantiodiscriminating and binds in the amino-azepaneseries only the (R)-enantiomer. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.026

文献信息

• [EN] PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIMIDINE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2010020675A1

  公开（公告）日：2010-02-25

  The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

  所披露的化合物涉及治疗与蛋白激酶相关的疾病。此外，还需要用于治疗、预防或改善癌症、移植排斥和自身免疫疾病的一个或多个症状的化合物。更进一步，还需要使用本处提供的化合物来调节蛋白激酶活性的方法，如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8和CDK9。
• PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
  申请人：NOVARTIS AG

  公开号：US20130184285A1

  公开（公告）日：2013-07-18

  The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

  所透露的化合物涉及蛋白激酶相关疾病的治疗和疗法。还需要用于治疗、预防或改善癌症、移植排斥和自身免疫性疾病一种或多种症状的化合物。此外，还需要使用此处提供的化合物调节蛋白激酶活性的方法，如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8和CDK9。
• Pyrrolopyrimidine compounds and their uses
  申请人：Besong Gilbert Ebai

  公开号：US08685980B2

  公开（公告）日：2014-04-01

  The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

  所披露的化合物与蛋白激酶相关的疾病的治疗和疗法有关。还需要用于治疗、预防或改善癌症、移植排斥和自身免疫性疾病的化合物。此外，还需要使用此处提供的化合物调节蛋白激酶活性的方法，如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8和CDK9。
• PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
  申请人：Novartis AG

  公开号：EP2331547B1

  公开（公告）日：2014-07-30
• US8415355B2
  申请人：——

  公开号：US8415355B2

  公开（公告）日：2013-04-09